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Background and Objective: Periodontal health is mediated by supressing 
microorganisms inducing a local inflammatory host response. Smoking may impair 
this process. This study compares gingival crevicular fluid levels of inflammatory and 
bone remodelling markers in heavy smokers and non-smokers following active and 
supportive periodontal therapy in chronic periodontitis patients.   
Materials and Methods: Gingival crevicular fluid (GCF) and subgingival plaque 
were collected from the deepest periodontal pocket in 50 patients, 25 smokers and 25 
non-smokers, at baseline (T0), following active (T1) and 12 months of supportive 
periodontal therapy (T2). Smoking status was validated measuring serum cotinine 
levels. GCF levels of 27 inflammatory and two bone remodelling markers were 
analysed using multiplex and singleplex micro-bed immunoassays, and subgingival 
plaque samples using checkerboard DNA-DNA hybridization. Amounts of markers in 
smokers and non-smokers were compared calculating the effect size.  
Results: Expression of inflammatory and bone-remodeling markers in smokers 
demonstrated an overall reduced effect size at T0 and T2 (p<0.001) More specifically, 
pro-inflammatory markers (p<0.001), chemokines (p=0.007) and growth-factors 
(p=0.003) at T0, osteoprotegerin (p=0.003) at T1, pro-inflammatory markers 
(p=0.019) and chemokines (p=0.005) at T2. At T2, IL-8 was detected in significantly 
higher levels in smokers. Ten different markers in non-smokers and none in smokers 
responded to periodontal therapy (p<0.05). An overall negative association was 
revealed between smoking and sub-groups of markers at sites presenting ≥105 red 
complex periodontal microbial species. 
Conclusion: Except for an upregulation of IL-8, smokers exhibited reduced GCF 
levels of several inflammatory markers at baseline and following active and supportive 
periodontal therapy.  Only inflammatory responses in non-smokers adapted to 
periodontal therapy. Apparently, there seems to be an immunosuppressant effect of 
smoking regulating the local inflammatory response and bone remodelling markers 






Cigarette smoking may affect periodontal tissues through modulating the immune 
response to periodontal pathogens. A dose-dependent hypo-immune inflammatory 
reaction has been suggested, mainly through systemic exposure following lung 
absorption (1-3). An additive local effect of smoking through direct exposure and 
absorption of toxic substances may adversely shift the periodontal equilibrium towards 
impaired repair and tissue breakdown (4, 5). Further, differences exist in composition 
of subgingival microbiota among smokers and non-smokers (6). Moreover, smoking 
appears to modulate composition, promote colonization of key periodontal pathogens, 
and influence bacterial aggregation (7, 8) rather than rate and amount of plaque 
accumulation (9, 10). 
Periodontal pathogens induce release of inflammatory and bone remodelling 
markers orchestrating innate and adaptive immune responses. The interaction and 
balance of these markers determine whether the tissue response remains stable or leads 
to destruction and disease progression (11). Gingival crevicular fluid (GCF), an 
inflammatory exudate or transudate collected from the gingival crevice, contains 
components of host-derived inflammatory markers (12). Thus, GCF analysis appears a 
non-invasive approach to investigate site-specific inflammatory responses and assess 
presence of various inflammatory markers (13). In smokers, site-specific tissue 
responses are clinically expressed by a specific attachment loss profile (14). However, 
site-specific mapping of inflammatory and bone-remodelling markers in smokers with 
chronic periodontitis reports conflicting results (15). A majority of studies have 
reported decreased local expression of some pro-inflammatory cytokines and 
chemokines in smokers (16-18) indicating an immunosuppressant effect of smoking 
that may increase susceptibility to periodontitis. Conversely, elevated expressions of 
chemokines and pro-inflammatory cytokines have also been reported in smokers (19, 
20). For bone remodelling, decreased GCF levels of osteoprotegerin (OPG) have been 
demonstrated following ≥20 years of smoking (21). As OPG blocks activation of 
receptor activator for nuclear factor kappa-B ligand (RANKL), the RANKL:OPG 
ratio, a surrogate marker for periodontal bone homeostasis, might increase in smokers 





Compromised healing following periodontal therapy in smokers is well 
documented (22-24) and impaired site-specific treatment outcomes may to some extent 
be explained by altered inflammatory responses (25). A few prospective studies have 
investigated the relationship between smoking and levels of pro-inflammatory 
markers, chemokines, and bone markers in GCF following periodontal therapy. IL-1β 
and TNF-α, are mostly studied; IL-1β levels decreased in smokers and non-smokers 
following 6 weeks of non-surgical therapy (26), whereas at 6 months the levels were 
reduced in non-smokers only (27). TNF-α did not change in smokers and non-smokers 
following 1 month of non-surgical therapy (28). At 6 months, however, a decreased 
level was observed in smokers (29). Interestingly, smoking seemed to upregulate the 
chemokine IL-8 following therapy (30), whereas OPG decreased in both smokers and 
non-smokers (31).   
Previous follow-up studies evaluating the local inflammatory status, have 
analysed a limited number of GCF markers. Multiplex immunoassay has the potential 
to simultaneously quantify multiple markers providing unique information necessary 
for a more complex understanding of the inflammatory response. By measuring 
several inflammatory markers over time, a site-specific tissue response to periodontal 
therapy can be monitored. Thus far, no prospective study has compared inflammatory 
responses in GCF following active and supportive periodontal therapy in smokers and 
non-smokers.  
This prospective study was designed to test the hypothesis that smoking 
downregulates the expression of the inflammatory molecules in GCF during treatment 
of chronic periodontitis. The primary aim was to investigate the GCF levels of 
inflammatory markers involved in periodontal inflammation and healing following 
active and 12 months of supportive periodontal therapy in heavy smokers and non-
smokers. The impact of smoking on the numbers of subgingival periopathogens 






MATERIAL AND METHODS 
Participants and study design  
From a sample of 80 patients, 40 smokers and 40 non-smokers, referred for 
periodontal treatment from general practitioners in a rural district of Norway, a 
subsample of  50 patients were enrolled in this single-arm clinical trial (for detail see 
Bunæs et al. 2015;(24). Briefly, criteria for inclusion were healthy subjects between 
35-75 years with moderate to severe chronic periodontitis (32) having at least four 
non-adjacent teeth with interproximal probing depth (PD) ≥6 mm, clinical attachment 
loss ≥5 mm, and bleeding on probing (BoP) (33, 34). Exclusion criteria were any 
current medical condition or medication affecting periodontal treatment and the use of 
systemic antibiotic or subgingival scaling in the 6 months before initiation of the 
study. Demographic data were obtained from the study participants by means of health 
forms and questionnaires. 
Based on predefined criteria, the 50 patients were allocated into two subgroups 
of 25 smokers reporting smoking >10 cigarettes/day for at least 5 years and with 
baseline pre-treatment (T0) serum cotinine level ≥300 ng/mL, and 25 non-smokers 
reporting never or no smoking the last 5 years and with T0 serum cotinine level ˂15 
ng/ml. Whole blood sample obtained from each patient was coagulated and 
centrifuged (700 x g for 10 min) and the serum was stored in aliquots at -80°C. Serum 
cotinine was assessed according to the manufacturer’s instructions of the serum 
enzyme immunoassay kit (Cotinine ELISA Kit, MyBioSource, San Diego, USA) 
measuring the absorbance at 450 nm using a microplate reader (FluoStar Optima 
V1.32 R2, BMG Labtech, Offenburg, Germany). 
The study protocol and informed consent form was approved by the 
Institutional Medical Research Ethics Committee (2011/151-6), University of Bergen, 
Norway followed the Helsinki Declaration of 1975, version 2008. All patients had read 
and signed a written consent prior to enrolment in the study. 
Clinical and microbiological examinations 
Clinical assessments, group allocations, and sampling selection were performed by a 
calibrated examiner (DFB). Clinical and microbiological sample collection were 





(T1), and following 12 months of supportive periodontal therapy (SPT) (T2). Mean 
time between T0 and T1 was 7.9 months and comprised non-surgical and surgical 
treatment. Patients presenting persistent PD >5 mm with BoP and adequate oral 
hygiene following non-surgical treatment were subjected to periodontal surgery. SPT 
was conducted every 3 months. PDs were recorded as the distance in mm from the 
gingival margin to the probeable base of the periodontal pocket, and clinical 
attachment level (CAL) as the distance in mm from the cemento-enamel junction or 
the margin of a dental restoration to the probeable base of the periodontal pocket. PD 
and CAL were measured using a periodontal probe (PCPUNC 15, Hu-Friedy, Chicago, 
IL, USA) at six sites per tooth rounding up to the nearest mm. Full mouth gingival 
bleeding was recorded as the percentage of sites showing bleeding after gentle probing 
(35) and full mouth dental plaque as the percentage of tooth surfaces with visible 
plaque following staining with disclosing solution (36). As a supplement to staining, 
the periodontal probe was used to discriminate between plaque and pellicle.  
At T0 subgingival plaque were collected by inserting two sterile paper points into the 
deepest periodontal pocket in each patient, and the procedure was repeated at the same 
site at T1 and T2. Prior to sampling, the site was carefully cleaned of supragingival 
plaque and kept dry. The paper points were gently inserted towards the apex of the 
pocket and kept in place for 20 sec (37) before removal and immersion into a pre-
reproduced sterile transport medium (PRAS Dental Transport Medium, Morgan Hill, 
CA,USA). The microbiological samples were analysed by DNA-DNA hybridization 
(checkerboard technique) at Microbiological Diagnostic Service, Department of Oral 
Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway. The analysis 
included detection and quantification of red (Porphyromonas ginigvalis, Taneralla 
forsythia, and Treponema denticola) and orange complex species (Prevotella 
intermedia, Prevotella nigrescens, Fusobacterium nucleatum subsp polymorphum, 
Fusobacterium nucleatum subsp nucleatum, Fusobacterium nucleatum subsp vincentii, 
and Parvimonas micra), and Aggregatibacter actinomycetemcomitans (Aa) (for details 
see Bunæs et al., 2015; (24).   
 Intra-examiner reliability of the examiner (DFB) was assessed using the 





0.92 and 0.96 for PD and between 0.93 and 0.96 for CAL. A post.hoc power analysis 
based on 25 heavy smokers and 25 non-smokers and with the level of significance (α) 
set to 0.05, gave a 71% power to detect a true difference of 0.5 mm. Prior to treatment, 
the hypothesis that is not possible to blind an examiner towards smoking status was 
tested in a pre-study sample of 30 chronic periodontitis patients, 16 smokers (>10 
cigarettes/day for at least 5 years) and 14 non-smokers (never or not in the last 5 
years). Calculus, plaque, and staining were removed and after rinsing with 0.2% 
chlorhexidine gluconate (Corsodyl, GlaxoSmithKline, London, UK) for 1 min, the 
examiner wearing a face mask scored the smoking status as yes or no. Twenty-eight 
patients (93%) were correctly identified as either non-smokers or smokers. Thus, the 
pre-study hypothesis was accepted (p<0.001) indicating that the attempt to blind the 
examiner with regard to smoking status was unsuccessful. 
GCF sampling and protein extraction 
GCF samples were collected using Periopaper strips, (PERIOPAPER Gingival Fluid 
Collection Strips, Oraflow Inc, Smithtown, NY, USA). Following removal of 
supragingival plaque with sterile curettes and cotton pellets, air dried, and isolated 
with cotton rolls, the deepest periodontal pocket in each participant was sampled. The 
paper strips were placed 1-2 mm into the entrance of the pocket and left in place for 30 
sec. Strips visually contaminated with blood or saliva were discarded. Sampled strips 
were immediately evaluated for GCF volume using the Periotron 8000 (Oraflow Inc, 
Smithtown, NY, USA). Strips were then immediately inserted into separate and dry 
microtubes, labelled, and stored at -80°C until further analysis.  
Tris-HCl buffer (110 μL) with a final concentration of 12mM at pH 7.6 was 
added to each tube for protein extraction. The tubes were shaken in 3x10 min before 
centrifuged (1800 x g for 10 min at 4°C) and subsequently the supernatant was 
pipetted to new tubes for protein quantification by a commercially available kit 
(Pierce™ BCA Protein Assay Kit, Thermo Scientific, Rockford, IL, USA). A plate 
reader (FLUOstar OPTIMA- BMG Labtech, Ortenberg, Germany) measured the 





Analysed markers  
Based on inflammatory and bone remodeling molecules involved in the periodontal 
healing process , the following cytokines were determined (diluted 1:4) using the 
multiplex kit Bio-Plex Human ProTM Assay (catalogue number LX10009222405) from 
Bio-Rad Inc., Hercules, CA, USA: IL-1β, IL-2, IL-1ra, IL-4, IL-5, IL-6, IL-7, IL-8, IL-
9, IL-10, IL-12, IL-13, IL-15, IL-17, Interferon-γ (IFN-γ), Basic Fibroblast Growth 
Factor (FGF), Granulocyte Colony Stimulating Factor (G-CSF), Eotaxin , 
Granulocyte-Monocyte Colony Stimulating Factor (GM-CSF), Interferon Inducible 
Protein-10 (IP-10), Monocyte Chemo-attractive Protein-1 (MCP-1), Macrophage 
Inflammatory Protein-1α (MIP-1α), Macrophage Inflammatory Protein-1β (MIP-1β), 
Platelet-Derived Growth Factor (PDGF), Regulated Upon Activation, Normally T-
Expressed, and Presumably Secreted (RANTES), Tumor Necrosis Factor-α (TNF-α) 
and Vascular Endothelial Growth Factor (VEGF). The standard curves for each 
marker present an overall range of 107489-0.064 pg/mL. 
The level of OPG and RANKL were assessed (diluted 1:4) using Milliplex MAP 
Kit Human Bone Magnetic Bead Panel (catalogue number HRNKLMAG-51K-01) 
from EMD Millipore corp. (Billerica, MA,USA) and a range of 30367-7.28 pg/mL 
recombinant markers was used to establish the standard curves. 
All measurements were performed using a Bio-plex 200®system (Bio-Plex 
Manager TM 6 software) based on the Luminex xMAP technology and the levels of all 
markers were reported in pg/30 sec and in pg/ml. 
Statistical analysis 
The Shapiro-Wilk test was applied to test for distribution of continuous variables. 
Descriptive statistics of clinical and demographical data were analysed using a chi-
square test for categorical variables (frequencies and percentages) and by a two-
sample independent t-test for continuous data (mean ± SD). As continuous data of the 
analysed mediators had a skewed distribution, natural logarithm transformation was 
employed to achieve normality prior to using the regression analysis to detect 
differences between smokers and non-smokers at T0, T1, and T2 and over time (T0 vs. 
T1, T0 vs. T2, and T1 vs. T2). Samples below detection of the standard curve were 





corrected for clustering of data within patients and the significance level of multiple 
comparisons were adjusted by the Sidak post-hoc test. A regression model, adjusted 
for age, gender, and education, and stratified by plaque (present/absent) or amount of 
red complex bacteria species (<105 / ≥105) was employed to test the overall association 
between the subgroups of quantified markers and smoking status.  
Amounts markers (pg/30 sec) in smokers and non-smokers were compared by 
calculating the effect size. Effect size, reported as Cohens`s coefficient, was calculated 
as the difference between the means of each marker in smokers and non-smokers 
divided by the standard deviations. Cohen`s coefficient is generally classified into 
small (0.2), medium (0.5), and large differences (≥0.8) and allows the size magnitude 
of the difference between smokers and non-smokers to be measured in a standardised 
scale. To present the results, forest-plots for the standardised effects sizes were used. 
An overall test of the difference between markers in smokers and non-smokers were 
analysed using fixed effects in the metan command (39).   
A p-value ≤0.05 was considered statistically significant. All analyses were 
conducted using Stata 14 (Stata Statistical Software: Release 14. StataCorp LP, 
College Station, TX, USA). 
 
RESULTS 
A total of 50 patients were evaluated, 25 smokers and 25 non-smokers. At T0, mean 
pack-year consumption in the smoking group was 37.0 (range 20-108) and mean 
cotinine level 478 mg/mL (range 340-861 mg/mL). For each patient, GCF samples 
were obtained from the same site at T0, T1, and T2. Data collection started April 2012 
and ended December 2014. Baseline patient related clinical and demographic 
characteristics according to smoking status are shown in Table 1. Compared with non-
smokers, significantly lower education level, higher mean PD and CAL were found for 
smokers. Mean patient related clinical measures of PD, CAL, BI, and PI, decreased 
significantly following ACT in smokers and non-smokers (p<0.001) and PD, BI, and 
PI increased significantly following SPT (p<0.05). Site-specific clinical and 
microbiological characteristics at T0, T1, and T2 are summarised in Table 2. No 





site-specific parameter at any time point, except for significantly higher numbers of Aa 
in non-smokers compared with smokers at T0 (p=0.041). 
GCF markers detected in less than 30% of the samples (IL-2, IL-5, IL-12, IL-
13, IL-15, Eotaxin, FGF, MCP-1 and RANKL) were removed from the analysis. The 
surveyed markers at T0, T1, and T2 were stratified by smoking status and comparisons 
of unadjusted means of the quantities are presented as amounts per 30 sec (pg/30sec) 
(Table 3a) and as concentrations (pg/mL) (Table 3b). Further analyses were conducted 
on the amounts of markers per 30 sec (40). Compared with non-smokers, significant 
lower levels were detected in smokers for TNF-α, IL-9, G-CSF, GM-CSF, IFN- γ, 
VEGF, MIP-1α and RANTES at T0, for OPG at T1, and for IL-9, IFN- γ, PDGF, MIP-
1α, MIP-1β, RANTES at T2. At T2, IL-8 was detected in significantly higher levels in 
smokers (p=0.034). Only non-smokers responded to treatment with significant changes 
in surveyed markers over time. From T0 to T1, significant reductions were revealed 
for IL-1β, TNF-α, IL-7, GM-CSF, IFN-γ, IL-10, VEGF and IP-10, and from T0 to T2 
for IL-1β and GM-CSF. A significant upregulation of TNF-α, IL-7, IL-9, IFN-γ, IL-
10, PDGF, and IP-10 was observed from T1 to T2. 
Based on the biological effects, the markers were distributed into subgroups of 
pro-inflammatory markers (IL-1β, IL-6, IL-9, IL-12 and TNF-α), anti-inflammatory 
markers (IL-4 and IL-10), chemokines (IL-8, IP-10, MCP-1, MIP-1α, MIP-1β and 
RANTES), growth factors (PDGF and VEGF), Th-1/Th-2 (INF-γ/ (IL-4, IL-6, IL-9, 
IL-10), and marker of bone remodelling (OPG). Since the markers were expressed in 
various amounts in smokers and non-smokers and measured in different scales 
(range107489-0.064), the magnitude of the differences between smokers and non-
smokers was calculated as effect size (Cohen`s coefficient). Figure 1a, b and c 
illustrate the size of the effect of smoking on the expression of marker and subgroup at 
T0, T1, and T2, respectively. At T0 smoking significantly reduced effect size for pro-
inflammatory markers (p=0.001), chemokines (p=0.007), and growth-factors 
(p=0.003), at T1 for OPG (p=0.003), and at T2 for pro-inflammatory markers 
(p=0.019) and chemokines (p=0.005). 
The subgroups were tested for overall association with smoking status after 





(<105/≥ 105) (Table 4). The numbers of tested sites in the analysis are not tabulated: 
plaque positive sites [n=96 (45 smokers / 51 non-smokers)], plaque negative sites 
[n=54 (30 smokers / 24 non-smokers], red complex positive sites [n=49 (23 smokers / 
26 non-smokers)], and red complex negative sites [n=101 (52 smokers / 49 non-
smokers)]. At plaque positive sites, a significant negative association with smoking 
status was revealed for pro-inflammatory markers, chemokines, and growth factors. 
For each group, adjusted analyses demonstrated an overall significant negative 
association with smoking status for plaque positive sites and an overall positive 
association for plaque negative sites. Further, in both unadjusted and adjusted 
analyses, negative associations were revealed between smoking status and groups of 
pro- and anti-inflammatory markers and OPG at sites presenting ≥105 red complex 
species. No significant associations were detected between smoking and groups of 
markers at sites presenting < 105 red complex species. The same tests were performed 
for orange complex species and Aa and a significant negative association between 
smoking and amounts of pro-inflammatory markers were only present for the adjusted 
analysis of sites < 105 orange complex species (p=0.033) (not tabulated). 
 
DISCUSSION 
Significantly smaller amounts of several inflammatory markers were detected in 
smokers compared with non-smokers at T0 and in the presence of increased clinical 
inflammation from T1 to T2. The expression of GCF markers at a site might be 
influenced by mean levels of PD and CAL (41). Sampling from the deepest PD in 
smokers and non-smokers rather from matched PD could have biased the analyses. 
However, the reliability of an overall reduced inflammatory response in smokers was 
substantiated by the fact that GCF samples were collected from sites exhibiting similar 
PD, CAL, BI, PI, and GCF volume in smokers and non-smokers. Another 
methodological concern when including smokers in clinical studies is the unsuccessful 
blinding of the examiner with regard to smoking status. This might in fact introduce a 
study bias. Further, strict sampling procedures and a trained operator intended to 
prevent a potential saliva contamination of the periopaper strips during the GCF 





An overall suppressed inflammatory response in smokers is supported by 
Tymkiw and suggests a local hypo-inflammatory state in smokers with chronic 
periodontitis (17). Reduction of important pro-inflammatory cytokines may initially 
alter local cytokine regulated inflammatory processes and persuade a dysfunctional 
response to stimuli such as bacterial lipopolysaccharides. In smokers at T0, significant 
reduced amounts of TNF-α, a multifunctional pro-inflammatory cytokine promoting 
cell migration and tissue destruction, might downregulate IL-1β and IL-6 and reduce 
production of chemokines (42). Though investigations of the impact of smoking on the 
expression of chemokines are limited, reduced amounts of chemokines in smokers 
have been confirmed by others (17, 43). In the present study, the slight rebound of 
periodontal disease during SPT coincided with increased amounts of MIP-1α, MIP-1β 
and RANTES at T2 in non-smokers only. As these chemokines facilitate migration 
and activation of specific types of leukocytes in response to periodontal pathogens 
(44), a downregulation of chemokines in smokers might reduce recruitment of 
inflammatory cells into infection sites. Chemokines also stimulate bone remodelling 
driving osteoblast migration (45) and reduced expression might negatively influence 
bone metabolism. A negative impact of smoking on bone homeostasis might be further 
supported by lower levels of OPG in smokers compared with non-smokers (significant 
at T1). RANKL was not detectable and an influence of smoking on the RANKL:OPG 
ratio can only be speculated upon. Nevertheless, increased bone loss in smokers with 
chronic periodontitis could be attributed to decrease in OPG and a subsequent increase 
in the RANKL:OPG ratio with a potential stimulation of osteoclasts. Another study in 
periodontitis patients with varying smoking status has reported reduced GCF levels of 
OPG in high pack-years consumption groups compared with non-smokers (21). 
IL-8 was the only inflammatory marker detected in significantly higher amounts 
in smokers compared with non-smokers. This is in agreement with previous studies 
(18, 20) indicating that smoking seems to upregulate the expression of IL-8 in a dose 
dependent manner (46). IL-8 is a chemokine associated with subclinical inflammation 
of initial periodontal lesions through migration of polymorphonuclear neutrophils 
(PMNs) to the infection sites (47, 48). Modulated inflammatory responses in smokers 





in smokers may increase chemotaxis and migration of dysfunctional PMN cells. 
Moreover, IL-8 has an important role in bone metabolism with direct actions on 
osteoclast activity and differentiation (50). Since IL-8 is suggested to play a crucial 
role in the pathogenesis of chronic periodontitis, an upregulation of IL-8 production in 
smokers might be a detrimental factor for impaired treatment outcome and recurrence 
of periodontal disease, especially in heavy smokers. 
None of the analysed inflammatory and bone remodelling markers responded 
significantly to treatment in smokers. This may strengthen the perception that smoking 
has a capacity to overwhelm and suppress local inflammatory response to periodontal 
pathogens (17, 51).  Non-smokers responded to treatment with changes in the amounts 
of inflammatory markers reflecting positive treatment responses and for several 
markers a significant reduction was observed from T0 to T1 followed by an increase 
from T1 to T2. The amounts of three principal pro-inflammatory markers, IL-1β, TNF-
α, and IFN-γ, reduced significantly as a response to therapy. INF-γ is related to Th-1 
response and inhibition containment of periodontal infection by enhancing phagocytic 
activity of macrophages and neutrophils(52), whereas IL-1β and TNF-α are the first 
markers emerging during the periodontal inflammation processes. IL-1β is a major 
mediator for periodontal disease and involved in inflammatory cell migration and 
osteoclastogenesis (53). Another longitudinal study reported  significant reduction of 
IL-1β  at 4 months following non-surgical periodontal therapy, supporting present 
findings  of a sustained decrease in IL-1β following treatment in non-smokers (47, 54). 
A persistent release of pro-inflammatory cytokines in smokers following active and 
supportive periodontal therapy may partially be explained by impaired resolution of 
inflammation and recurrence of periodontal disease following therapy.  
As a response to active periodontal therapy, all clinical parameters improved 
significantly in smokers and non-smokers whereas the total numbers of red complex 
species, Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola, 
were significantly reduced in non-smokers only. The non-significant reduction of red 
complex species observed between T0 and T1 in smokers, could stimulate local 
inflammatory responses maintaining elevated amounts of GCF markers at T1. 





aggravation of the biofilm and delayed reduction of red complex species in smokers 
following ATP. Nevertheless, following SPT, a significant reduction of total red 
complex species took place in smokers without significant changes in the amounts of 
inflammatory markers. A dysregulated inflammatory response to periopathogenic 
bacteria in smokers was further supported by negative associations between smoking 
and groups of inflammatory markers at plaque positive sites and at sites harbouring 
≥105 of red complex species. It would be of interest to investigate the plaque with 
high-through put techniques, whereas DNA-DNA checkerboard hybridization 
technique has a rather crude accuracy.  Keystone pathogens other than P Gingivalis 
may be determined for host response in smokers and Parvimonas Mirca is considered 
a keystone pathogen associated with deep pockets in smokers (7, 55). Nevertheless, 
the majority of immune responses to periopathogens are known to occur locally within 
the periodontal tissues, in GCF, and between cells conjugated to another, rather than to 
systemic responses (56, 57). However, in smokers, the amounts of inflammatory 
markers appeared to be modulated not only by site-specific factors as presence of 
plaque and a high number of red-complex species, but also by the complex systemic 
influence of cigarette smoke.  
In general, expressed markers in GCF using multiplex assays and ELISA`s are 
detected with similar trends, but not directly comparable due to methodological 
variations (58), varying amounts of markers, and measurements at different scales. 
Two recent reviews support reporting of total marker content per 30 sec, especially for 
longitudinal studies, together with smoking status, and clinical parameters at collection 
sites (40, 53). They argue that low levels of gingival crevicular fluid volumes 
following periodontal therapy can negatively influence calculation of the 
concentration. Reduced GCF and BoP in smokers compared with non-smokers (59, 
60) , could be an explanation for the suppressed response and downregulation of 
markers collected per 30 sec in smokers. Related to progression of chronic 
periodontitis, it appears to be an association between BoP in both smokers and non-
smokers (3, 61). Nevertheless, GCF volume did not vary significantly between 
smokers and non-smokers and analysis with concentrations of markers reported the 





differences in the amounts among markers are standardized and forest plots illustrate 
the magnitude of the difference between smokers and non-smokers. Further, non-
pooled samples and an objective validation of smoking status, reduced the number of 
confounding factors in the comparisons of GCF markers following periodontal therapy 
in smokers and non-smokers and to some extent weight up for the relatively low 
sample size. 
The results herein confirmed the study hypothesis by a suppressed 
inflammatory reaction presented as reduced expression of GCF markers in heavy 
smokers, especially for pro-inflammatory markers and chemokines. Furthermore, 
smokers did not respond to periodontal therapy with significant changes in the 
amounts of any marker in GCF and a negative association was detected between 
smoking and expression of markers at plaque positive sites. Future prospective studies 
should contextualize the local tissue responses in smokers within the influence of a 
larger systemic effect of smoking.  
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a. Forest plot for overall standardized effect of smoking at T0 for markers in GCF. 
b. Forest plot for overall standardized effect of smoking at T1 for markers in GCF.  












Table 1. Baseline patient related characteristics, presented as mean 





Male1 32 % (8)  52 % (13) 0.158 
Elementary school (≤ 9 years)1 76  % (19)  36 % (9) 0.004 
Age2 56.6 (2.07)  57.9 (1.86) 0.658 
Body mass index2 22.9 (1.32)  23.62 (1.69) 0.742 
Number of teeth2 23.5 (1.19)  25.8 (0.48) 0.076 
Probing depth2 3.9 (0.12)  3.3 (0.10) 0.001 
Clinical attachment level2 4.6 (0.19)  4.0 (0.11) 0.008 
Bleeding index2 69.7 (4.00)  66.5 (3.06) 0.532 
Plaque index2 51.6 (3.96)  56.3 (3.78)  0.415 
1 chi-square test 
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